CHF-1024, a DA 22 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload

S. Masson, S. Chimenti, M. Salio, M. Torri, F. Limana, R. Bernasconi, L. Calvillo, D. Santambrogio, N. Gagliano, B. Arosio, G. Annoni, R. Razzetti, S. Bongrani, R. Latini

Research output: Contribution to journalArticlepeer-review


We compared the effects of an ACE inhibitor, captopril, with those of a DA 2-dopaminergic/α 2-adrenergic receptor agonist (CHF-1024) on neuroendocrine activation and cardiac fibrosis in a model of pressure-overload hypertrophy. Interrenal aortic stenosis was performed in 89 rats, treated with CHF-1024 (0.33, 2 or 6 mg kg -1 day -1), or captopril (1 g/L). Hemodynamic variables were recorded. Cardiac and renal weights, plasma aldosterone, renin activity and urinary catecholamine excretion were measured, as well as cardiac collagen. Blood pressure was lower in stenotic animals treated with CHF-1024 compared to vehicle (161±10 vs 219±10 mmHg, p2/α2 agonist CHF-1024 effectively blunts adrenergic drive and cardiac fibrosis in a rat model of pressure overload.

Original languageEnglish
Pages (from-to)131-138
Number of pages8
JournalCardiovascular Drugs and Therapy
Issue number2
Publication statusPublished - 2001


  • α -adrenoceptor agonist
  • DA -dopaminergic agonist
  • Fibrosis
  • Norepinephrine
  • Renovascular hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'CHF-1024, a DA <sub>2</sub>/α <sub>2</sub> agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload'. Together they form a unique fingerprint.

Cite this